- Home
- NSPR vs ATYR Comparison
NSPR vs ATYR Comparison
Compare NSPR & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSPR | ATYR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 83.3M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSPR | ATYR |
|---|---|---|
| Price | $1.82 | $0.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $4.00 | ★ $4.20 |
| AVG Volume (30 Days) | 36.7K | ★ 1.2M |
| Earning Date | 03-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,310,000.00 | N/A |
| Revenue This Year | $65.32 | N/A |
| Revenue Next Year | $103.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $0.64 |
| 52 Week High | $2.93 | $7.29 |
Technical Indicators
Market Signals| Indicator | NSPR | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 41.25 |
| Support Level | $1.61 | $0.67 |
| Resistance Level | $2.51 | $0.85 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 50.00 | 5.33 |
Price Performance
Historical ComparisonAbout NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).